PFE

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken FisherFisher Asset Management $2.9B105M shares AddQ1 2026 $1.7B $25.77 $26.20
Charles BrandesBrandes Investment Partners $256M9.1M shares AddQ1 2026 $41M $25.77 $26.20

Congress Trades

Actor	Trade Size	Last Transaction	Amount Range	Price	Current Price
Ro KhannaDemocrat $8.0k292.6 shares BuyApr 13, 2026 $1k-$15k $27.34 $26.20
Susan M. CollinsRepublican $33k1.3k shares BuyFeb 3, 2026 $15k-$50k $25.77 $26.20
James French HillRepublican $175k7k shares OtherDec 31, 2025 $100k-$250k $24.90 $26.20
Ron L WydenDemocrat $8.0k342.6 shares OtherJun 3, 2025 $1k-$15k $23.35 $26.20
Ron L WydenDemocrat $8.0k342.6 shares SellJun 3, 2025 $1k-$15k $23.35 $26.20
Rob BresnahanRepublican $33k1.3k shares BuyMay 15, 2025 $15k-$50k $25.64 $26.20

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Bourla AlbertDirector, Officer: Chairman & CEO --23 shares Grant / ExerciseMay 29, 2026 Disclosure amount unavailable23 shares -- $26.20

News

247wallst.comEarn $5,000+ Yearly With These 4 Dividend Stocks247wallst.comJun 9

zacks.comAmneal and Pfizer GLP-1 Deal: New Growth Lever?zacks.comJun 9

zacks.comPFE Gets FDA Nod for Expanded Use of Hemophilia Drug Hympavzizacks.comJun 9

forbes.comTrouble Ahead For GLP-1 Drugs As Health Plans Stop Payingforbes.comJun 9

247wallst.comWatch Out, Rising Capex Could Turn Today's Cash Cows Into Dogs247wallst.comJun 8

Trade PFE

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

CEO: Albert Bourla
IPO Date: Jun 1, 1972

Market Data

Open: $25.73
High: $25.88
Low: $25.47
Volume: 26.2M
52W High: $28.75
52W Low: $23.11

Valuation

Market Cap: $146B
Enterprise Value: $209B

Financials

Free Cash Flow: $9.1B
Revenue: $63B
Net Income: $7.8B
Cash: $1.1B
Debt: $67B

Events

EarningsAug 4

EPS est. 0.68